Instructions for Amlodipine Aspartate Tablets
Release time:
2020-07-31
Approval Date: October 23, 2006
First Amendment Date: June 20, 2010
Second Amendment Date: May 05, 2015
Amlodipine Aspartate Tablets Instruction
Aspartic acid Amlodipine Tablets
Please read the instruction carefully and use
[Drug Name]
generic name under the guidance of a doctor: amlodipine aspartate tablets
trade name: liside
English name: Aspartic acid Amlodipine Tablets
Chinese pinyin: Men dong an suan an lu di ping plan-
[ingredients] the main ingredient of this product is L-amlodipine aspartate
chemical name: 2-1 [2-aminoethoxy] methyl] -4-1 (2-chlorophenyl) -1,4-dihydrogen -6-methyl pyridine -3,5-3-ethyl -5-methyl ester L-a-aspartic acid salt.
Chemical Structural Formula:

Molecular Formula: C20H25CIN205 C4H7N04
Molecular Weight: 541.99
[Character] This product is white or white-like sheet
[Indications] It can be used alone or in combination with other antihypertensive drugs to treat hypertension
[Specification] 5mg (based on amlodipine)
[Usage and Dosage] Usually the initial dose is 5mg (one sheet) once a day, but the elderly, frail, liver damage patients and patients with other antihypertensive drugs, the initial dose can be 2.5mg (half a tablet), once a day. Dosage adjustment should be based on the clinical response of the individual patient, the maximum dose can be increased to 10mg (two tablets), once a day. This product is combined with thiazide diuretics, beta blockers and angiotensin converting enzyme inhibitors without dose adjustment.
[Adverse Reactions] The more common adverse reactions are headache, edema, fatigue, insomnia, nausea, abdominal pain, flushing, palpitations and dizziness. Less common adverse reactions are angina, hypotension, bradycardia, orthostatic hypotension, pruritus, rash, dyspnea, weakness, muscle cramps, and dyspepsia. This product is similar to other calcium antagonists, there are few reports of adverse reactions of myocardial infarction and chest pain, and these adverse reactions can not be clearly distinguished from the patient's own underlying disease; no abnormal laboratory parameters related to this product have been found.
[Contraindications] Patients allergic to dihydropyridine calcium antagonists are contraindicated.
[Precautions]
L. Patients with impaired liver function: As with all other calcium blockers, the half-life of this product is prolonged when liver function is impaired, but the corresponding recommended dose has not yet been determined. Therefore, this product should be used with great care in this case.
2. Patients with renal failure: This product is widely metabolized into inactive metabolites, and only 10% of the drugs are excreted in the original form through urine. Therefore, the change of blood drug concentration is not related to the degree of renal damage. Patients with renal damage can use normal doses. This product is not dialysis.
3. This product, such as other calcium ion blockers, can rarely have gingival hyperplasia, which mostly occurs during 1-9 months of treatment, but symptoms and hyperplasia can be improved l-21 weeks after drug withdrawal.
4. There is no need to stop the drug before surgery, but the anesthesiologist must know to use this drug for treatment.
. The following conditions are prohibited:
① Severe hypotension:
② Aortic stenosis.
[Use for pregnant and lactating women] The safety of this product for pregnant and lactating women has not been established. In animal experiments, rats were given 10 mg/kg of this product. In addition to delayed delivery and prolonged labor, intrauterine death increased 5 times and the number of littermates decreased by 50%. Therefore, this product can only be used when there is no other safer alternative drug and the disease itself is more dangerous to mother and child. There are no reports on whether this product is discharged into milk.
[Children's medication] There is no information on this product for children.
[Elderly Medication] The peak time of blood drug concentration of this product is similar in elderly and young patients. The area under the curve (AUC) of elderly patients is increased, the elimination half-life is prolonged, and the clearance rate is decreased. It has been reported that older patients were as well tolerated as younger patients when receiving similar doses of amlodipine. Therefore, the elderly patients can use the normal dose, but it is advisable to start with a smaller dose, and then gradually increase the appropriate.
[Drug Interactions]
(1) Narcotics: Inhalation of hydrocarbon drugs with this product can cause hypotension.
(2) non-steroidal anti-inflammatory drugs, especially indomethacin: with this product can weaken the hypotensive effect, may be related to the inhibition of prostaglandin synthesis and (or) cause water, sodium retention.
(3) beta blockers: well tolerated with this product, but can cause excessive hypotension, rare cases can increase the possibility of congestive heart failure.
(4) Estrogen: Use with this product can increase fluid retention and increase blood pressure.
(5) Sulfopyrone (sulfinpyrazone): combined with this product can increase the protein binding rate of amlodipine and change the blood drug concentration.
(6) Lithium preparations: When used with this product, it can cause neurotoxicity, such as nausea, vomiting, diarrhea, ataxia, tremor and (or) numbness, and should be used with caution.
(7) Sympathomimetic amines may attenuate the antihypertensive effect of this product.
[Drug Overdose] Existing data suggest that severe overdose can lead to excessive dilatation of peripheral blood vessels, followed by significant and lasting systemic hypotension, bradycardia, rare II or III degree atrioventricular block, and cardiac arrest in a few patients. The former should be given intravenous dopamine, norepinephrine treatment. The latter should be given atropine, isopropyl kidney, calcium chloride treatment, if there are indications should be placed pacemaker.
[Pharmacological Toxicology]
Pharmacological Effects
This product is a calcium ion influx blocker (I. e. calcium channel blocker or calcium ion antagonist), which can selectively inhibit calcium ion from flowing into vascular smooth muscle and myocardial cells across the membrane, especially for vascular smooth muscle. This product directly dilates vascular smooth muscle, dilates peripheral arterioles, reduces peripheral resistance (afterload), and significantly dilates coronary arteries. This product has a negative inotropic effect in vivo, but has no effect on the sinoatrial node and atrioventricular node.
Toxicological Study
Acute Toxicity in Mice: The LD 50 of L-aspartate amlodipine bulk drug administered by gavage is 80.2 mg/kg(95% confidence limit is 71.3-90.2 mg/kg); The LD 50 for intraperitoneal injection is 62.1 mg/kg(95% confidence limit is 55.0-70.1 mg/kg).
Genotoxicity: Mutagenicity test results indicate no drug-related gene or chromosome level mutagenicity.
Reproductive toxicity: General reproductive toxicity test, oral administration of amlodipine 10 mg/kg/day (based on body surface area, about 8 times the maximum recommended human dose of lOmg) to rats has no damage to fertility. Oral administration of 10 mg/kg of amlodipine (about 8 times and 23 times the maximum recommended human dose of 10mg in terms of body surface area, respectively) to pregnant rats and rabbits during organogenesis had no teratogenic effect on embryos. However, oral administration of amlodipine 10 mg/kg 14 days before mating and pregnancy in rats significantly reduced the number of littermates (about 50%), increased intrauterine mortality (about 5 times), and prolonged pregnancy and labor. Adequate and well-controlled trials have not been conducted in pregnant women, so pregnant women should only take this product during pregnancy when their potential benefits are large and potentially dangerous to the fetus.
It is not clear whether this product is excreted in human milk. In view of the lack of information in this regard, it is recommended to stop using it during lactation.
Carcinogenicity: Amlodipine is carcinogenic in rats and mice for two years. Mixed food doses of 0.5,1.25, and 2.5 mg/kg/day are non-carcinogenic. The highest dose (calculated by body surface area, the mouse dose is equivalent to the maximum recommended clinical dose of 10mg, while the rat dose is twice) is close to the maximum tolerance of mice.
[Pharmacokinetics] It is reported in the literature that this product is well absorbed orally and is not affected by food intake. The plasma protein binding rate is about 97.5, the blood drug concentration reaches the peak value 6-12 hours after single administration, the absolute bioavailability is about 64-80%, the apparent distribution volume is about 21L/kg, the final elimination half-life is about 35-50 hours, once a day, after 7-8 days of continuous administration, blood drug concentration reached steady state. This product is widely metabolized by the liver into inactive metabolites, 10% of which are excreted as original drugs and 60% as metabolites through urine.
【Storage】 Shaded, sealed and stored in a dry place..
【Packing】 Aluminum-plastic plate packaging, each small carton containing seven or fourteen pieces.
[Validity] 24 months.
[Implementation Standard] WS-(X-101)-2005Z
[Approval Document No.] Guoyao Zhun Zi H20020487
[Production Enterprise]
Enterprise Name: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
Address: No. 58 Gaofan Section, Baitang Downline, Wucheng District, Jinhua City, Zhejiang Province
Tel: 0579-82661998 (Consultation) 0579-82131973 (Sales)
Fax
:
More information
Shanghai North Carolina passed the "Little Giant" annual acceptance
Recently, Shanghai Beika Pharmaceutical Technology Co., Ltd., a new member of Jianfeng Pharmaceutical Co., Ltd., successfully passed the annual acceptance of Shanghai science and technology "little giant" cultivation enterprise. In order to promote the independent innovation of enterprises, improve the core competitiveness of enterprises, enhance the competitive advantage of enterprises in domestic and foreign industries, and speed up the construction of scientific and technological innovation, Shanghai North Carolina applied for the Shanghai "Science and Technology Innovation Action Plan" science and technology "little giant" cultivation project in 2016 and was approved, becoming a member of 87 "little giant" cultivation enterprises in Shanghai in that year, with a project implementation period of 2 years. During the period of the Little Giant Cultivation Project, North Carolina completed the re-identification of Shanghai high-tech enterprises and the identification of Songjiang District Enterprise Technology Center. Songjiang District Enterprise Technology Center was evaluated as excellent, passed the certification of Shanghai Academician Expert Workstation, and passed the acceptance of Shanghai Patent Work Pilot Enterprises. A total of 4 invention patents were authorized, 12 invention patents were applied, 2 registered trademarks were applied, and 4 enterprise standards were formulated, there are 22 product testing reports. In 2017, Songjiang District's industry-university-research innovation project was approved and the project target was completed. Tinib drugs and their intermediates in non-small cell lung cancer (NSCLC) are the dominant varieties in North Carolina. In order to improve the existing tinib product line and consolidate the economic benefits and market share of this kind of products, North Carolina has not only conducted research and development on the latest generation of precision medical special-effect drugs such as cabozantinib (Cabozantinib) and ceritinib (Ceritinib), but also focused on the development of drug intermediates for tinib stars, which are hot spots in the pre-clinical research and development of generic drugs.
2020
07-31
The company held the 2017 Board of Directors and the Board of Supervisors
On April 20, Jiang Xiaomeng, chairman of the group company, presided over the 3rd meeting of the 10th board of directors of the company, and deliberated and passed 15 proposals and reports including the 2017 work report of the board of directors and the 2017 work report of the general manager. The general manager's report pointed out that in 2017, the company focused on the general work policy of "grasping trends, precise development, strengthening standards, improving quality, improving management, and enhancing efficiency", grasping the opportunities brought by economic structure optimization and industrial upgrading, and accelerating innovation Development, in-depth management integration, continuous improvement of management level, improvement of enterprise operation efficiency, strengthening of marketing expansion, and steady promotion of product sales growth, remarkable results have been achieved in technological innovation and technological transformation, the financial structure has been continuously improved, and the core competitiveness of enterprises has been further strengthened. The company achieved operating income of 2.827 billion yuan for the whole year, an increase of 18.81 percent over the same period last year, and realized net profit attributable to owners of the parent company of 348.4943 million yuan, an increase of 22.18 percent over the same period last year, another record high, with earnings per share of 1.01 yuan, achieving the best operating performance in the peak 60-year development process. Total assets at the end of the year were 4.176 billion yuan, an increase of 4.53 percent over the same period last year. In 2017, with the in-depth implementation of the national "One Belt One Road" initiative, cement off-peak production has been comprehensively promoted, industry environmental protection supervision has been further improved, energy conservation and consumption reduction supervision has become stricter, mergers and acquisitions have deepened, industry self-discipline awareness has continued to increase, and the cement industry supply-side structural reform has started.
2020
07-31
The peak represents the two sessions of Jinhua
From March 30 to April 3, March 31 to April 4, the second session of the seventh session of the Jinhua CPPCC and the third session of the seventh session of the Jinhua Municipal people's Congress were held successively. Three deputies to the National People's Congress and members of the CPPCC attended the meeting and actively offered suggestions and suggestions for the future development of Jinhua. Among the three performance suggestions put forward by Jiang Xiaomeng, chairman of the group company, two are about the real economy. He said that the development of the real economy in Jinhua City has encountered many bottlenecks in recent years. On the one hand, the operating costs of real enterprises have increased year by year and the profits have decreased, which has affected the development confidence and investment enthusiasm of entrepreneurs; on the other hand, the current new economic concepts are emerging one after another, and social capital is emerging. The loss of reality has caused a greater impact on the real economy. To this end, Jiang Xiaomeng suggested starting from five aspects to help Jinhua's real economy get rid of its predicament, that is, to create a good environment for investment and enterprises to enter households, such as competitive land elements, supporting public environmental protection facilities, and reasonable supporting industries. Development policies, abundant labor resources, etc.; the government conducts in-depth research on land, factories, taxes, subsidies, incentives, etc, further introduce various preferential policies and measures that are attractive and can stimulate the economic vitality of real enterprises; the combination of government investment promotion and "business investment promotion", and introduce corresponding guidance and incentive policies, through the introduction of business in gold enterprises, it is more convincing and easier to succeed; pay attention to helping existing local industrial enterprises and enhance their enthusiasm; vigorously promote outstanding business operators and entrepreneurs, and create a good atmosphere of respect for entrepreneurs, to boost the enthusiasm of the majority of entrepreneurs to invest in the construction of return home. About Small and Micro Enterprises
2020
07-31
Determination of "60th Anniversary of Entrepreneurship" Series of Activities
In 1958, the first batch of peak people started from scratch and began to build the first cement plant in Jinhua at the foot of peak mountain. Today, 60 years later, the small cement plant has developed into a cross industry and cross regional listed company. In order to commemorate the 60th anniversary of Jianfeng's entrepreneurship, the company decided to organize a series of activities. The activity plan has been basically determined by the group company's office meeting, and an activity leading group led by Jiang Xiaomeng, chairman of the group company, has been established. The group office meeting discussed and decided that the commemorative activities are based on the principles of grand, simple and meaningful. While enlivening the company's cultural atmosphere, concentrating efforts, and enhancing the friendship and exchange of all employees, it also inherits and carries forward the essence of corporate culture accumulated over a long period of time. In order to carry out the activity smoothly, the company decided to set up a leading group for the celebration of the 60th anniversary of entrepreneurship, with Jiang Xiaomeng, chairman of the group company, as the group leader and Yu Jianhong, general manager of the group company, as the deputy group leader. The group members include Huang Jinlong, Zhang Fengliang, Xiang Chongping, Chen Tianci, Zhu Jianwei, Lan Xiaolong and Qin Xuping. There is a celebration working group. The series of commemorative activities mainly include media publicity with the theme of "publicizing peak achievements and establishing peak image"; carrying out manuscripts, calligraphy, painting, photography, speeches and other activities with the theme of "knowing peak and loving peak" and the history of Jianfeng Group's entrepreneurial development as the content; a series of cultural and sports activities with the theme of "strengthening physique and revitalizing peak; the activity of" sending warmth "with the theme of" caring for employees and caring for employees "; the group company with the theme of" infinite scenery at the peak"
2020
07-31
Determination of "60th Anniversary of Entrepreneurship" Series of Activities
In 1958, the first batch of peak people started from scratch and began to build the first cement plant in Jinhua at the foot of peak mountain. Today, 60 years later, the small cement plant has developed into a cross industry and cross regional listed company. In order to commemorate the 60th anniversary of Jianfeng's entrepreneurship, the company decided to organize a series of activities. The activity plan has been basically determined by the group company's office meeting, and an activity leading group led by Jiang Xiaomeng, chairman of the group company, has been established. The group office meeting discussed and decided that the commemorative activities are based on the principles of grand, simple and meaningful. While enlivening the company's cultural atmosphere, concentrating efforts, and enhancing the friendship and exchange of all employees, it also inherits and carries forward the essence of corporate culture accumulated over a long period of time. In order to carry out the activity smoothly, the company decided to set up a leading group for the celebration of the 60th anniversary of entrepreneurship, with Jiang Xiaomeng, chairman of the group company, as the group leader and Yu Jianhong, general manager of the group company, as the deputy group leader. The group members include Huang Jinlong, Zhang Fengliang, Xiang Chongping, Chen Tianci, Zhu Jianwei, Lan Xiaolong and Qin Xuping. There is a celebration working group. The series of commemorative activities mainly include media publicity with the theme of "publicizing peak achievements and establishing peak image"; carrying out manuscripts, calligraphy, painting, photography, speeches and other activities with the theme of "knowing peak and loving peak" and the history of Jianfeng Group's entrepreneurial development as the content; a series of cultural and sports activities with the theme of "strengthening physique and revitalizing peak; the activity of" sending warmth "with the theme of" caring for employees and caring for employees "; the group company with the theme of" infinite scenery at the peak"
2020
07-30
Determination of "60th Anniversary of Entrepreneurship" Series of Activities
In 1958, the first batch of peak people started from scratch and began to build the first cement plant in Jinhua at the foot of peak mountain. Today, 60 years later, the small cement plant has developed into a cross industry and cross regional listed company. In order to commemorate the 60th anniversary of Jianfeng's entrepreneurship, the company decided to organize a series of activities. The activity plan has been basically determined by the group company's office meeting, and an activity leading group led by Jiang Xiaomeng, chairman of the group company, has been established. The group office meeting discussed and decided that the commemorative activities are based on the principles of grand, simple and meaningful. While enlivening the company's cultural atmosphere, concentrating efforts, and enhancing the friendship and exchange of all employees, it also inherits and carries forward the essence of corporate culture accumulated over a long period of time. In order to carry out the activity smoothly, the company decided to set up a leading group for the celebration of the 60th anniversary of entrepreneurship, with Jiang Xiaomeng, chairman of the group company, as the group leader and Yu Jianhong, general manager of the group company, as the deputy group leader. The group members include Huang Jinlong, Zhang Fengliang, Xiang Chongping, Chen Tianci, Zhu Jianwei, Lan Xiaolong and Qin Xuping. There is a celebration working group. The series of commemorative activities mainly include media publicity with the theme of "publicizing peak achievements and establishing peak image"; carrying out manuscripts, calligraphy, painting, photography, speeches and other activities with the theme of "knowing peak and loving peak" and the history of Jianfeng Group's entrepreneurial development as the content; a series of cultural and sports activities with the theme of "strengthening physique and revitalizing peak; the activity of" sending warmth "with the theme of" caring for employees and caring for employees "; the group company with the theme of" infinite scenery at the peak"
2020
07-31